Intellus Advisors LLC Takes Position in Johnson & Johnson (NYSE:JNJ)

Intellus Advisors LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 4,049 shares of the company's stock, valued at approximately $586,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. IFS Advisors LLC grew its position in Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after acquiring an additional 100 shares during the period. Bay Harbor Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter worth about $32,000. RPg Family Wealth Advisory LLC bought a new position in Johnson & Johnson during the 3rd quarter valued at about $35,000. Runnymede Capital Advisors Inc. acquired a new position in Johnson & Johnson in the fourth quarter valued at about $38,000. Finally, NewSquare Capital LLC grew its stake in Johnson & Johnson by 145.8% during the fourth quarter. NewSquare Capital LLC now owns 290 shares of the company's stock worth $42,000 after buying an additional 172 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Down 1.3 %

Shares of JNJ traded down $2.15 during trading hours on Tuesday, reaching $161.14. The stock had a trading volume of 7,455,754 shares, compared to its average volume of 7,086,516. The firm has a 50-day moving average of $157.70 and a 200 day moving average of $156.14. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The company has a market cap of $388.32 billion, a P/E ratio of 24.23, a P/E/G ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99.

Remove Ads

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm's quarterly revenue was up 5.3% on a year-over-year basis. During the same period last year, the business posted $2.29 earnings per share. On average, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were issued a dividend of $1.24 per share. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.08%. Johnson & Johnson's payout ratio is presently 74.59%.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Citigroup reduced their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a research report on Wednesday, December 11th. StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 25th. Morgan Stanley decreased their price objective on Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 23rd. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research report on Monday, March 10th. Finally, Bank of America raised their price target on Johnson & Johnson from $159.00 to $171.00 and gave the company a "neutral" rating in a report on Wednesday, March 5th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus price target of $171.33.

Insider Activity at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the business's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.